Azithromycin vs placebo or usual care: Adverse events during treatment period
Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Azithromycin vs placebo or standard of care alone Any adverse events during the study period · people with moderate to severe disease (WHO scale 4 to 9) Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty). Antibiotics for the treatment of COVID‐19 (2021) · Cochrane Headline outcomes only | RR 1.2 [0.92, 1.57] | 3 studies · 355 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.